This proposal is for support to allow the continued growth and development of the Eastern Cooperative Oncology Group (ECOG) program at the UPMC Health System (UPMC) and University of Pittsburgh Cancer Institute (UPCI). UPMC and UPCI are strongly committed to the development and clinical evaluation of effective new therapies for cancer. UPCI has received NCI designation as a comprehensive cancer center with broad basic science strength and depth in a range of multi-modal disease centers that relative closely to ECOG. UPCI has received NCI designation as a comprehensive cancer center with broad basic science strength and depth in a range of multi-modal disease centers that relative closely to ECOG. The objectives of the ECOG program at UPCI and UPMC are: 1) To increase accrual of patients to ECOG studies at the main institution and its affiliates. 2) To continue to augment the scientific participation of the university faculty and affiliate members in ECOG activities, both clinical and laboratory. 3) To further enhance the translation of institutional laboratory science programs related to cancer therapy into ECOG pilot and groupwide studies (biologic response modifiers, and experimental therapeutics). 4) To increase the linkage of UPCI resource laboratories such as the Immunologic Monitoring Laboratory and programs such as biological therapeutics to ECOG. 5) To maintain and improve the high quality of complete, accurate, and timely data submitted for ECOG investigations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA039229-18
Application #
6512494
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1985-06-01
Project End
2004-04-30
Budget Start
2002-05-10
Budget End
2003-04-30
Support Year
18
Fiscal Year
2002
Total Cost
$254,385
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Bakhru, Pearl; Zhu, Meng-Lei; Wang, Hsing-Hui et al. (2017) Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight 2:
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Langer, Corey J; Socinski, Mark A; Patel, Jyoti D et al. (2016) Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol 39:441-7
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Willis, Scooter; De, Pradip; Dey, Nandini et al. (2015) Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene 4:129-41
Schneider, Bryan P; Li, Lang; Radovich, Milan et al. (2015) Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21:5082-5091

Showing the most recent 10 out of 59 publications